Evidence map›Paper›PMID 35297992›Full record

ArticleMolecular cancer research : MCR2022

Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma.

Andrew Wallace, Sima P Porten, Amy A Lo, Daniel Oreper, Nicolas Lounsbury, Charles Havnar, Ximo Pechuan-Jorge, Oliver A Zill, Maxwell V Meng

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. FAPNature communications · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Andrew Wallace *Department of Oncology Bioinformatics, Genentech, Inc., San Francisco, California.
Sima P Porten *Department of Urology, University of California, San Francisco, California.
Amy A LoDepartment of Research Pathology, Genentech, Inc., San Francisco, California.ORCID 0000-0002-8614-6734
Daniel OreperDepartment of Oncology Bioinformatics, Genentech, Inc., San Francisco, California.
Nicolas LounsburyDepartment of Oncology Bioinformatics, Genentech, Inc., San Francisco, California.
Charles HavnarDepartment of Research Pathology, Genentech, Inc., San Francisco, California.
Ximo Pechuan-JorgeDepartment of Cancer Immunology, Genentech, Inc., San Francisco, California.
Oliver A Zill *Department of Oncology Bioinformatics, Genentech, Inc., San Francisco, California.ORCID 0000-0002-4329-2790
Maxwell V Meng *Department of Urology, University of California, San Francisco, California.
Bioinformatics Institute · SGGenesys (United States) · USUniversity of California, San Francisco · USCancer Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) with venous tumor thrombus (VTT) arising from the primary tumor occurs in approximately 10% of cases and is thought to represent more advanced disease. The intravascular nature of VTT suggests that it may serve as a source for hematogenous metastases. RCC with VTT and distant metastasis provides unique opportunities to examine the origins and emergence timing of these distinct tumor lesions, and to identify molecular correlates with disease state. We performed multi-region exome and RNA-sequencing analysis of 16 patients with RCC with VTT, with eight patients also having sequenced metastasis, to identify genomic alterations, biological pathways, and evolutionary processes contributing to VTT and metastasis, and to ask whether metastasis arises directly from or independent of VTT. No specific genomic alterations were associated with VTT. Hallmark copy-number alterations (deletions of 14q, 8p, and 4q) were associated with metastasis and disease recurrence, and secondary driver alterations tended to accumulate in metastatic lineages. Mismatch repair mutational signatures co-occurred across most tumors, suggesting a role for intracellular DNA damage in RCC. Robust phylogenetic timing analysis indicated that metastasis typically emerged before VTT, rather than deriving from it, with the earliest metastases predicted to emerge years before diagnosis. As a result, VTT in metastatic cases frequently derived from a metastatic lineage. Relative to the primary tumor, VTT upregulated immediate-early genes and transcriptional targets of the TNFα/NF-κB pathway, whereas metastases upregulated MTOR and transcriptional targets downstream of mTORC1 activation. IMPLICATIONS: These results suggest that VTT and metastasis formation occur independently, VTT presence alone does not necessarily imply more advanced disease with inevitably poor prognosis.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsThrombosisHumansNeoplasm Recurrence, LocalPhylogeny

Identifiers

PMID35297992
PMCPMC9381131
OpenAlexW4220999441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.